

# Tania Fleitas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3731422/publications.pdf>

Version: 2024-02-01

19  
papers

466  
citations

758635

12  
h-index

839053

18  
g-index

19  
all docs

19  
docs citations

19  
times ranked

882  
citing authors

#	ARTICLE	IF	CITATIONS
1	The LEGACy study: a European and Latin American consortium to identify risk factors and molecular phenotypes in gastric cancer to improve prevention strategies and personalized clinical decision making globally. BMC Cancer, 2022, 22, .	1.1	2
2	Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study. British Journal of Cancer, 2021, 125, 1261-1269.	2.9	14
3	Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer. ESMO Open, 2020, 5, e000847.	2.0	21
4	Precision Medicine to Treat Advanced Gastroesophageal Adenocarcinoma: A Work in Progress. Journal of Clinical Medicine, 2020, 9, 3049.	1.0	12
5	Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer. Cancers, 2020, 12, 3611.	1.7	30
6	Personalized Medicine: Recent Progress in Cancer Therapy. Cancers, 2020, 12, 1009.	1.7	123
7	Assessing molecular subtypes of gastric cancer: microsatellite unstable and Epstein-Barr virus subtypes. Methods for detection and clinical and pathological implications. ESMO Open, 2019, 4, e000470.	2.0	35
8	Molecular profile in Paraguayan colorectal cancer patients, towards to a precision medicine strategy. Cancer Medicine, 2019, 8, 3120-3130.	1.3	2
9	In the literature: June 2019. ESMO Open, 2019, 4, e000547.	2.0	3
10	A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer. ESMO Open, 2019, 4, e000532.	2.0	13
11	NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in <i>HER2</i> -Amplified Gastric Cancer. Clinical Cancer Research, 2019, 25, 1639-1649.	3.2	47
12	In the literature: December 2018. ESMO Open, 2018, 3, e000468.	2.0	0
13	Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity. Clinical Cancer Research, 2017, 23, 5406-5415.	3.2	29
14	MassARRAY determination of somatic oncogenic mutations in solid tumors: Moving forward to personalized medicine. Cancer Treatment Reviews, 2016, 49, 57-64.	3.4	13
15	First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors. Clinical Cancer Research, 2016, 22, 877-885.	3.2	59
16	Epigenetic changes in localized gastric cancer: the role of RUNX3 in tumor progression and the immune microenvironment. Oncotarget, 2016, 7, 63424-63436.	0.8	12
17	Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology. Oncotarget, 2016, 7, 22543-22555.	0.8	11
18	Deregulation of <i>ARID1A</i> , <i>CDH1</i> , <i>cMET</i> and <i>PIK3CA</i> and target-related microRNA expression in gastric cancer. Oncotarget, 2015, 6, 26935-26945.	0.8	35

#	ARTICLE	IF	CITATIONS
19	A first-in-human trial of RG7116, a glycoengineered monoclonal antibody targeting HER3, in patients with advanced/metastatic tumors of epithelial cell origin expressing HER3 protein.. Journal of Clinical Oncology, 2013, 31, 2522-2522.	0.8	5